Datopotamab deruxtecan-dlnk improved duration of response by roughly 5 months compared with chemotherapy in first-line mTNBC.
Rebecca Dent, MD
Advertisement
Articles by Rebecca Dent, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Final EMBARK Data Show “Almost Unprecedented” Reduction in Risk of Death With Enzalutamide Plus ADT in Biochemically Recurrent Prostate Cancer
2
From Mutation to Medicine: Targeted Therapies in Lung Cancer
3
Addressing Drug Resistance in Lung Cancer
4
Tar-200 Plus Anti–PD-1 Therapy Shows Promising Neoadjuvant Activity in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
5
